Brought to you by 
Biogen, Ionis pen sixth CNS agreement; could be worth in excess of $1bn; option exercised
05 Jan 2022
Executive Summary
Partners Biogen Inc. and Ionis Pharmaceuticals Inc. have formed a new ten-year deal aimed at developing new antisense therapies for a wide range of neurological conditions.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com